Abstract:Abstract Background Ulcerative colitis (UC) is a heterogeneous, chronic inflammatory disease, with many different drivers of pathogenesis, characterised by inflammation of the colon mucosa, relapsing–remitting disease course and variable response to therapy. Around 30–55% of patients with UC are refractory to treatment during the induction phase, despite the availability of molecular targeted agents. Recent studies have investigated a potential link between eosinophilia and increased disease activity, poorer clinical outcomes and response to therapy. Dupilumab is a fully human monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13, key and central drivers of type 2 inflammation in multiple diseases. It is approved for treatment of atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic oesophagitis and prurigo nodularis. The phase 2 LIBERTY-UC SUCCEED (NCT05731128) study is designed to investigate the efficacy and safety of dupilumab versus placebo in adults with moderately to severely active UC with an eosinophilic phenotype. Methods Approximately 100 patients will be randomised 1:1 to receive dupilumab or placebo treatment for 52 weeks. Key inclusion criteria include age ≥18 years, moderately to severely active UC (modified Mayo score 5–9), biomarker enrichment, and inadequate/non-response, loss of response, or intolerance to standard biologic therapy and/or oral corticosteroids, ASA compounds, immunomodulators or small molecules. Key exclusion criteria include severe extensive colitis (defined by current hospitalisation, requirement for surgery for UC within 12 weeks of screening), prior medical history of eosinophilic colitis, or presence of intestinal failure. Participants who qualify will have the opportunity to receive open-label dupilumab. Results The primary endpoint is proportion of patients in clinical remission at Week 24, defined as a modified Mayo score of ≤2 with a stool frequency score ≤1, a rectal bleeding score = 0 and a Mayo endoscopic subscore ≤1 with absence of friability. Higher scores indicate greater disease severity. Secondary endpoints include the proportion of patients achieving clinical response by modified Mayo score at Week 8, 24 and 52, and incidence of treatment-emergent or serious adverse events. Conclusion The phase 2 LIBERTY-UC SUCCEED study will evaluate the efficacy and safety of dupilumab therapy in adults with moderately to severely active UC with an eosinophilic phenotype. This will aid in addressing the need for precision medicine approaches to treat UC.

A Phase 3 Trial of Dupilumab for People With Chronic Obstructive Pulmonary Disease and Elevated Peripheral Blood Eosinophil Counts

Dupilumab for COPD with Blood Eosinophil Evidence of Type 2 Inflammation

Dupilumab reduces exacerbations and improves lung function in patients with chronic obstructive pulmonary disease and emphysema: Phase 3 randomized trial (BOREAS)

Dupilumab improves respiratory symptoms in patients with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Dupilumab efficacy in patients with COPD and type 2 inflammation irrespective of mortality risk score

Dupilumab improves lung function in non-exacerbators with moderate-to-severe COPD with type 2 inflammation in phase 3 BOREAS trial

Dupilumab efficacy and safety in patients with moderate-to-severe COPD with type 2 inflammation: pooled analysis of BOREAS and NOTUS

Dupilumab improves quality of life in non-exacerbators with moderate-to-severe COPD and type 2 inflammation: phase 3 BOREAS trial

Safety of dupilumab in T2 airways conditions: focus on eosinophilia across trials and real-life evidence

Eosinophilia and Adverse Effects of Dupilumab for Respiratory Indications: A Real-World Setting

Dupilumab Reduces Exacerbations and FeNO Levels and Improves Asthma Control with Inhaled Corticosteroid Withdrawal: a Phase 2 Study

Dupilumab-induced eosinophilia in patients with diffuse type 2 chronic rhinosinusitis

Clinical effectiveness and safety of dupilumab in patients with chronic obstructive pulmonary disease: A 7-year population-based cohort study

S661 Dupilumab Improves Multiple Histopathologic Endpoints in Children With Eosinophilic Esophagitis: 52-Week Results From the Phase 3 EoE KIDS Trial

Eosinophil Cationic Protein Variation in Patients with Asthma and CRSwNP Treated with Dupilumab

[Chronic obstructive pulmonary disease (COPD): eosinophilia and novel drug therapies]

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases

Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age

Laboratory Safety of Dupilumab, and Its Effect on Inflammatory Biomarkers, in Chinese Adults with Moderate-to-Severe Atopic Dermatitis: an Analysis of a Randomized, Double-Blind Phase III Study

Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management

P726 A phase 2 study investigating the efficacy and safety of dupilumab versus placebo in adults with moderately to severely active ulcerative colitis with an eosinophilic phenotype